Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking for VIPR,SKGO,BEDA would like bit lower PPS but wouldnt mind holding skgo or beda for a few weeks if needed for a profit
sold on elis dreams
anx PTFO anyone in?
PFNO AH news
ParaFin Issuance of Preferred Shares Paid for With Bearer BondsFont size: A | A | A7:31 PM ET 3/11/10 | Marketwire
ParaFin Corporation (PINKSHEETS: PFNO): The Directors of ParaFin Corporation In response to multiple inquiries from shareholders and potential shareholders, ParaFin Corporation felt compelled to put out a statement on the company's Bearer Bond holdings.
On January 27, 2010, ParaFin Corporation released an annual report reflecting an asset of US$3.63 billion represented by 2,400 Bearer Bonds issued June 16, 2000 dated for redemption on June 16, 2010. The 2,400 Euro Bearer Bonds were issued by a major European Bank, have a face value of 1,000,000 Euros each and have accumulated interest at 5.5% from the issuance date.
Bearer Bonds of this denomination and amount are typically reserved solely for and held only by banks and large financial institutions. After the original issuance, these Bonds were acquired by and delivered to a single individual. In an effort to promptly liquidate the assets of this individual's estate, the Trustee of the individual's estate negotiated the Agreement with ParaFin.
To finance the Exploration and Exploitation of the 6.06 million Acre Hydrocarbon Farm-out Agreement in the Republic of Paraguay, ParaFin Corporation was in the process of selling an issue of Preferred Shares. The Subscription Agreement negotiated by ParaFin with the Trustee for the sale of the Preferred Shares allowed the Trustee to pay ParaFin Corporation US$3.63 billion by the delivery to ParaFin of 2,400 Bearer Bonds issued June 16, 2000 dated for redemption on June 16, 2010. Under the Agreement, ParaFin is entitled to 100% of the accumulated interest owed to date.
The Preferred shares issued by ParaFin have a legend printed on the face of the Certificate stating they are "Redeemable, Retractable on Demand Non-Voting Shares Issue Price US$1,000,000 per Share... secured only by funds from the sale or redemption of the 2,400 5.5% Euro Bearer Bonds."
ParaFin retained expert Forensic Document Examiners and has done substantial due diligence regarding the Bonds over the past two years. ParaFin is now working with private consultants who are in the process of setting meetings with the top executives at the issuing Bank in order to negotiate the redemption of the bonds. Legal opinions received by ParaFin confirmed that whoever is in possession of the Bonds in hand has the right to redemption.
Contact:
ParaFin
Internet: www.parafincorp.com
Telephone: (877) 613-3131
e-Mail: ceo@parafincorp.com
SOURCE: ParaFin Corporation
http://www.parafincorp.com
mailto:ceo@parafincorp.com
ANX news
ADVENTRX Receives Brand Name Acceptance for ANX-530Font size: A | A | A8:00 AM ET 3/12/10 | PR Newswire
RELATED QUOTES
3:59 PM ET 3/11/10
Symbol Last % Chg
ANX 0.21 0.00%
Quotes delayed at least 15 minutes
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the U.S. Food and Drug Administration (FDA) has accepted the proposed proprietary name "Exelbine(TM)" for the Company's product candidate ANX-530 (vinorelbine injectable emulsion).
"We are pleased with the FDA's response to our proprietary name request and look forward to continued regulatory progress on ANX-530," said Brian M. Culley, Chief Executive Officer of ADVENTRX.
Following completion of its review process, the FDA concluded that "Exelbine" is acceptable provided the information presented by ADVENTRX regarding the safety of interchanging ANX-530 with other vinorelbine injectable products is confirmed during review of an ANX-530 New Drug Application (NDA).
As previously announced, the Company submitted an NDA for ANX-530 to the FDA in December 2009. In March 2010, the Company announced that it had received a refusal-to-file letter from the FDA regarding its ANX-530 NDA submission. In the letter, the FDA indicated that the data included in the December 2009 NDA submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. The FDA identified only this one chemistry, manufacturing and controls (CMC) reason for the refusal to file. ADVENTRX has requested a face-to-face meeting with the FDA to understand its requirements and define the path to a successful filing of an ANX-530 NDA at the earliest possible time.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that FDA determines that there is a safety concern related to interchanging ANX-530 with other vinorelbine injectable products; the risk that the FDA's requirements for an ANX-530 NDA to be accepted for review do not justify continued development of ANX-530; ADVENTRX's dependence on the success of ANX-530, and increased uncertainty as to whether ANX-530 will receive regulatory approval or be commercialized successfully; the potential that FDA may not accept a resubmitted ANX-530 NDA for review, or that the bioequivalence data and other information included in the ANX-530 NDA may not adequately support bioequivalence with Navelbine; the potential that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials, and that FDA may require ADVENTRX to perform additional non-clinical or clinical studies; the potential for FDA to impose other requirements to be completed before or after approval of the ANX-530 NDA; the risk that ADVENTRX will have insufficient capital to support its operations during the FDA review of an ANX-530 NDA, should a resubmitted ANX-530 be accepted; the risk that ADVENTRX will pursue development activities at levels or on timelines, or will incur unexpected expenses, that shortens the period through which its operating funds will sustain it; the risk that ADVENTRX will be unable to raise sufficient additional capital to commercialize ANX-530, if an ANX-530 NDA is approved; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
and you only get 1 commission?
so do you do AON?
if I do a limit order and dont (AON)
LOTT0 me aswell, I am still figuring out the .000s If i do market order only get charged one commission but it could be filled at higher pps. If limit (AON) seems I dont get filled often. If not AON i can get several commssions charged through etrade
isnt this march 4th news?
RVGD
anyone chart this or follow it? I has moved down 16^ on 6 mill vol. If it moves up that easy could be a nice entry at .0004-5
im listening go on
MBTG UP 29% FRom my post
MBTG NEWS!!
Columbia University Division of Pediatric Oncology Chooses Millennium Biotechnologies' Resurgex Select(R) for Multi-Site Clinical TrialFont size: A | A | A8:34 AM ET 3/3/10 | GlobeNewswire
Millennium Biotechnologies Group Inc. (OTCBB:MBTG), a leader in the development of targeted nutritional products in the Clinical Nutrition Market and Sports Nutrition Market, announced today that Columbia University has chosen Resurgex Select(R) to be the focus of a multicenter clinical trial to test its effectiveness in treating pediatric oncology patients, due to its unique composition.
The clinical study is the first ever to test the effectiveness of the proprietary nutritional blend contained in Resurgex's nutritional supplement in preserving lean muscle mass and quality of life in pediatric cancer patients. The clinical study protocol titled "Promass Nutrition Intervention Using High Calorie Protein Supplement to Preserve Lean Body Mass," is scheduled to occur during the summer of 2010 and last for 12 weeks, pending I.R.B. approval next month. The study will take place at four separate test sites: Columbia University Division of Pediatric Oncology, St. Jude Children's Research Hospital (SJCRH), Alberta Health Services, and the Regional Cancer Center (RCC) at Capital Health.
Because of Millennium Biotechnologies' clinical recognition for its Resurgex Select(R) nutritional supplement, Columbia University initiated the trial with the Company to determine the supplement's ability to be a highly effective treatment in minimizing or eliminating the ravaging effects of cancer treatment on children's bodies.The Company has agreed to provide the clinical study with its Resurgex product and four "Multi-Frequency, Segmented Bioelectric Impedance" machines needed to measure lean body mass.
The specific objectives of the clinical trial are to validate that the Company's Resurgex Select's(R) acceptance in pediatric patients based on its taste, color and texture as well as its effectiveness in preventing the loss of lean body mass and impact on quality of life, as measured by the Peds QL standard, in children with brain tumors that are undergoing therapy.
"The Company is optimistic that its Resurgex supplement will provide a greater improvement in the nutrition of pediatric oncology patients than any competing products, and both parties are anxious to launch this trial immediately following I.R.B. approval next month. Additionally, we believe that Resurgex's superior taste and texture will give it a higher level of acceptability by children than all other nutritional products,, which is a key component of this trial's success," stated Mark Mirken, Chairman and CEO of Millennium Biotechnologies Group. "The initiation of this trial by such prestigious institutions is clearly a reflection of Resurgex's pre-eminent recognition as a highly targeted nutritional supplement with proven success in cancer clinics, hospitals and with dieticians who are thought leaders in oncology," added Mirken.
For more information about the Company's products, please visit www.resurgex.com.
About Millennium Biotechnologies Group, Inc.
Millennium's six marketed products form an advanced line of nutritional formulas. Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium also created Surgex(TM) sports nutrition formula to address the nutritional concerns of professionals, Olympic, and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immuno-compromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function.
Resurgex Essential(TM) and Resurgex Essential Plus(TM) are comprehensive, calorically dense formulas that meet and succeed the nutritional requirements of the assisted living community.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of1934. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of the Company and SPI set forth herein and those preceded by or that include the words ``believes,'' ``expects,'' ``given,'' ``targets,'' ``intends,'' ``anticipates, "plans,'' ``projects,'' ``forecasts'' or similar expressions, are "forward-looking statements". Although the Company's management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties, which could cause the Company's future results to differ materially from those anticipated. The Company assumes no obligation to update any of the information contained or referenced in this press release.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Millennium Biotechnologies Group, Inc.
CONTACT: Seal Point Consulting, LLC
267-364-5407
Investors@sealpointconsulting.com
i already looked it up before i posted originally
if you would have posted the news I might bite but out of principal I cannot buy
lcre .0001s gone ask at .0002 182 million traded
LCRE NEWS
Lecere on the Verge of Deploying Its Software, Reaffirms: NO REVERSE SPLIT!Font size: A | A | A9:01 AM ET 3/1/10 | BusinessWire
Software start-up Lecere(TM) Corporation (Pink Sheets: LCRE) has reaffirmed that it does not intend to do a reverse split in at least the entire year of 2010.
According to Jim Morris, Chairman and CEO, "Lecere is focused 100% on developing its software and obtaining customers. We do not intend to play 'pink sheet games' with our stock now or at any time in the future."
Lecere's initial deployment of its fully web-based, full-featured Point of Sales software for restaurants is scheduled for April 30, 2010. Features include (1) clock in/clock out, (2) manager, hostess, server, expediter, kitchen, and bar roles with screen, handheld, and printer screen views, (3) handheld, tableside order entry, (4) order item progress and alerts appropriately sent to the various roles' views (e.g. 'bar' role sees drink orders on any associated screens and/or printers, with expediter and server notified when an item is ready), (5) off-the-floor credit card scan (credit card never leaves the owner's view), (6) menu definition, (7) tables definition with auto/manual (as appropriate, e.g. 'seated' as long as there are open tickets), and (8) table state mgmt: open, seated, dirty, and closed.
Said Morris, "We are making steady progress in the development of our software, and we are in discussions with distribution partners who can deliver hundreds of customers to Lecere in 2010 alone. We are also targeting a few early-adopter sites that will enable us to prove our product is world-class, cloud-computing software, and that we are fully capable of extending and supporting rollouts to enterprise customers. The Lecere team has vast experience over many years in developing and supporting software. We have done it many times before, and we will certainly do so with this new software. Our team is determined to bring Lecere to a position of leadership in the hospitality software industry, and we will not rest until that goal has been achieved."
Lecere will provide a webinar demo of its software to potential, qualified restaurant customers or distribution partners. Please email jim dot morris at lecere dot com if you would be interested in seeing a webinar demo.
About Lecere(TM) Corporation
Lecere Corporation (Pink Sheets: LCRE) of Portland, Oregon, develops and markets Lecere FIRMS(TM), an integrated, Web-based suite of interactive restaurant management software that runs on handheld wireless devices. FIRMS helps restaurants reduce their operational costs while enhancing their customers' experiences for increased revenues and profits.
Lecere and FIRMS are trademarks of Lecere Corporation. All other legal marks are the property of their respective owners.
SOURCE: Lecere Corporation
Lecere Corporation
Jim Morris, 503-781-4828
IVIT NEWS
Invicta Group Signs Agreement With Les Walgreen and Appoints Him Director of Product DevelopmentFont size: A | A | A8:31 AM ET 3/1/10 | Marketwire
Invicta Group Inc., (http://www.ivitgroup.com) (PINKSHEETS: IVIT) is pleased to announce the signing of an agreement with Les Walgreen and his appointment to Director of Product Development. Mr. Walgreen brings over 20 years of valuable experience to help increase the revenues and profits of the Invicta Group.
Les Walgreen is the great-grandson of Charles Rudolph Walgreen Sr (the founder of Walgreens) and the son of Charles R. Walgreen III C.E.O. from 1971-1998 and who recently retired from the board as Chairman Emeritus. Les worked for the Walgreen Co. starting as a stock boy at age 16. By the age of 25, he was involved in the store systems of the Marketing Systems & Development department. In 1995, Les started Walgreens.com and it immediately made an impact on recruitment and by 1996 had the very first scannable coupons for customers to print and take to the stores. By mid 1996 Les founded Manta Media, a web, print and multimedia design and marketing firm. Real Estate was his next passion in the 2000's, however his foresight that the market would soon be unstable, jumped right back into what he knows best: retail. Les is also a Partner in the Cold Mountain Group, Maxwell Street, LLC, and Peaux Deaux Products and Peaux Deaux Productions. His first executive producer role in film had him throwing the biggest and best party at Sundance in 2008 at the world famous Harry O's.
Les Walgreen said, "I am very excited to work with Paul Sorkin and the Invicta Group team. I have been working on a number of great projects recently and the Invicta Group is the perfect partner to help me create, develop, and market the products and projects I am developing. I have always been an entrepreneur and a visionary and I love what the Invicta Group has put together. I have been very impressed with their infrastructure, their ability to utilize the economies of scale so effectively, and with what they have accomplished so quickly. I feel I can help the company grow significantly and create a big upside for everyone involved. 2008 was a pivotal time in my career, I partnered with Cold Mountain Group to bring emerging products to the retail world. My career has gone full circle, I'm still a stock boy, only difference is now I do it for 1,000's of shelves at a time! My father built the Walgreen Co. into what it is today by making sure to hire the brightest and best. With the Invicta Group, Paul has done exactly that and it makes a lot more sense for me to be part of the exceptional team that he has already built!"
CEO of the Invicta Group, Paul Sorkin, said, "Les Walgreen is an incredible addition to our team and I'm looking forward to working with him on a number of projects. Mr. Walgreen shares our vision and has the ability to help multiple divisions of Invicta and add new ones. Les brings in a whole arsenal of new clients, partners, and contacts that can immediately benefit from all of the services we offer. We expect his experience, skill, and relationships to help us increase our printing and packaging division tremendously, while using his entertainment relationships to expand IMAGE Chicago Magazine in print, online, and at events, and his ability to place products in mass retail outlets will benefit everyone involved. We feel this is a huge turning point in our company's ability to take things to the next level."
About Invicta Group, Inc.
INVICTA GROUP, Inc. (PINKSHEETS: IVIT) is a full service multimedia management and marketing company. The Invicta Group is a conglomerate that utilizes shared resources to create synergies between their projects and companies and creates a lower cost of entry into the marketplace and almost instant start up capabilities for new products, services, and clients. www.IVITgroup.com
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plan, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks described in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements that may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Media Contact
info@IVITgroup.com
Investor Relations Contact
1-312-473-5234
info@IVITgroup.com
SOURCE: Invicta Group Inc.
mailto:info@IVITgroup.com
mailto:info@IVITgroup.com
nice BEDA news, I thought last few days were a good price for it and just had a commission loss sale of nspt was looking for it or vipr. Great for those who got it
global*** thoughts on tphm rd 2??
HYBE- looks like runable news anyone have an L2 UP????
wow! let me know how that works out for you
have i been seeing more sells than buys since news posted?
is that vid suitable for my virgin eyes? I am a etrade baby afterall
PIHN toooooo da moooooon tommorrow ;)
yeah kind of funny rich but its moving
Anyone get DKAM this morning?
dkam up 70%
DKAM 134 mill in float
MEXCOR distributes to 21 states
As the first one here since dawn I big good morning
POPN tankage
the word yesterday was to the mooon!
dont do it lotto tfzi boomage! WEEEEEEEEEEEEEEEEEEE
yeah i hope lotto either got out on the upticks or had just nibbled and can buy on what i think will be another leg down
if that was bgoi bottom i missed it
sorry i guess i need to be more clear, those are trades I made money on.
really!!!!! weeeeeeeeeeeee
i AM watching BGOI aswell but cant tell if she wasnt .00 first